GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-08-15 DOI:10.1158/1078-0432.CCR-24-0486

Franco Locatelli, Concetta Quintarelli

引用次数: 0

Abstract

Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication. See related article by Fischer-Riepe et al., p. 3564.

查看原文本刊更多论文

GD2 靶抗原与 CAR T 细胞：探戈需要两个以上的细胞吗？

过去十年来，嵌合抗原受体（CAR）T 细胞已成为治疗某些血液恶性肿瘤的突破性癌症疗法。将这种疗法的成功应用于实体瘤具有挑战性。在此，我们将讨论在这一临床适应症中提高 CAR T 细胞疗效的潜在策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.

文献相关原料

公司名称	产品信息	采购帮参考价格